Form 8-K - Current report:
SEC Accession No. 0001178913-24-003695
Filing Date
2024-11-14
Accepted
2024-11-14 09:03:31
Documents
16
Period of Report
2024-11-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zk2432197.htm   iXBRL 8-K 50729
2 EXHIBIT 99.1 exhibit_99-1.htm EX-99.1 223165
7 image00002.jpg GRAPHIC 39316
  Complete submission text file 0001178913-24-003695.txt   527227

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA slxn-20241114.xsd EX-101.SCH 4740
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE slxn-20241114_def.xml EX-101.DEF 18263
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE slxn-20241114_lab.xml EX-101.LAB 27748
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE slxn-20241114_pre.xml EX-101.PRE 20505
19 EXTRACTED XBRL INSTANCE DOCUMENT zk2432197_htm.xml XML 6551
Mailing Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606
Business Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606 972-8-6286005
Silexion Therapeutics Corp (Filer) CIK: 0002022416 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42253 | Film No.: 241457615
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)